Danaher Corporation $DHR Stock Position Lifted by Wealth Enhancement Advisory Services LLC

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in Danaher Corporation by 1.8%, acquiring an additional 3,659 shares, bringing its total holdings to 210,828 shares valued at $42.84 million.
• A number of analysts have issued varying price targets for Danaher, with a consensus rating of "Moderate Buy" and an average price target of $246.35.
• Danaher Corporation plans to pay a quarterly dividend of $0.32 per share on October 31st, representing a 0.7% dividend yield.

Wealth Enhancement Advisory Services LLC increased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 1.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 210,828 shares of the conglomerate's stock after purchasing an additional 3,659 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Danaher were worth $42,840,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of DHR. Hills Bank & Trust Co lifted its stake in shares of Danaher by 0.3% in the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock worth $3,693,000 after acquiring an additional 53 shares during the period. Sageworth Trust Co raised its holdings in Danaher by 2.3% during the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock worth $493,000 after purchasing an additional 54 shares in the last quarter. 1834 Investment Advisors Co. raised its holdings in Danaher by 3.3% during the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock worth $342,000 after purchasing an additional 54 shares in the last quarter. Bruce G. Allen Investments LLC lifted its position in Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate's stock worth $92,000 after purchasing an additional 54 shares during the period. Finally, Rakuten Securities Inc. boosted its stake in Danaher by 33.3% during the 1st quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock valued at $46,000 after purchasing an additional 56 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 11.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

DHR has been the topic of a number of research reports. Barclays reissued an "overweight" rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Evercore ISI lowered their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $245.91.

Danaher Trading Down 0.3%

NYSE DHR traded down $0.63 on Tuesday, hitting $189.83. 488,619 shares of the company were exchanged, compared to its average volume of 4,124,075. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The firm has a market capitalization of $135.92 billion, a P/E ratio of 40.39, a price-to-earnings-growth ratio of 2.70 and a beta of 0.75. The company's 50 day moving average price is $200.02 and its 200-day moving average price is $198.03.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period last year, the firm posted $1.72 earnings per share. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio is presently 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.